written by reader Diabetes Company From IPO Insider

By ingthing, April 15, 2020

Today Justin Spittler teased a diabetes company. Anyone been able to crack which company it is?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.



This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
April 15, 2020 9:59 pm

interesting, where is this at?

Matt B
Matt B
April 17, 2020 9:56 am

I was wondering this as well, here is the limited info on the pitch:

It’s no secret that America’s getting older.

By 2060, the number of Americans 65 and older will double to nearly 100 million people.

This isn’t just playing out in the United States. Populations in many large Asian and European countries are also aging. In fact, 26% of the population in Japan is already over the age of 65. In Italy, Germany, and Portugal, that figure tops 20%.

This is great news for the entire medical device industry. Older people account for the vast majority of medical expenses. In the United States, people age 55 and over account for 56% of all healthcare spending… despite making up just 29% of the population.

You can see why investing in medical devices for the long haul is a “no-brainer”…
And most investors would do just fine by owning IHI.

But there’s a special group of medical device stocks that will deliver even more explosive gains in the coming years.

I’m talking about the companies that are tackling the diabetes crisis.

Diabetes is a disease that occurs when your blood glucose (or blood “sugar”) is too high. It affects 463 million adults (1 in 11) worldwide. Last year, an estimated 4.2 million deaths were caused by diabetes.

It’s a full-blown crisis. Thankfully, disruptive companies are tackling this crisis head on… helping people with diabetes live longer, healthier lives.

Dexcom, Inc. (DXCM) is one of those companies. Dexcom makes glucose monitoring systems. These devices help people living with diabetes monitor their glucose levels.

You can see below that its stock is skyrocketing. It’s jumped 131% since last April… and over 500% since October 2017. During that stretch, Dexcom outperformed IHI by more than 12X.

Insulet Corporation (PODD) is another red-hot “diabetes stock.”

It sells insulin pumps for people living with diabetes. PODD has spiked 93% since last April… and an incredible 479% since the start of 2017. Like Dexcom, PODD also outpaced IHI by a wide margin during that explosive run.

Tandem Diabetes Care, Inc. (TNDM) is another high-flying example. Like Insulet, Tandem makes insulin pumps.

Its share price has surged 2,727% since February 2018. That’s enough to turn every $10,000 invested into over $28,000! During that run, Tandem outperformed IHI by nearly 400X!

These types of companies should continue to soar in the coming years as they tackle one of the country’s biggest epidemics.

People with diabetes are depending on cutting-edge medical devices and other solutions more than ever…
According to a 2018 study, the number of US adults with diabetes is projected to hit 39.7 million by 2030. That would represent a 53% spike from today. At that point, nearly 13% of the US population would suffer from diabetes.

By 2060, it’s estimated that 60.6 million adults (17.9% of the population) will suffer from diabetes.

Not only that, the number of elderly people (ages 65 years and older) with diabetes is expected to increase nearly 4X by 2060.

And unlike coronavirus, there will be no vaccine for diabetes. That means people with diabetes are relying on the very best medical device companies.

This is great news for disruptive companies at the forefront of this megatrend…
It’s why medical device companies like Dexcom, Insulet, and Tandem would make a great addition to most investors’ portfolios.

But there’s one “diabetes stock” that stands head and shoulders above the rest.

Unlike the companies mentioned above, this company doesn’t build insulin pumps or other medical devices. Instead, it uses data science and advanced technologies like artificial intelligence (AI) to help people with diabetes live healthier lives.

It’s a “next-generation” diabetes stock. And I’d bet that less than 1 out of 100 investors have even heard of it